Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| ASM International | ASML | Pfizer | |
|---|---|---|---|
| Moat rating | narrow The 2025 annual report (published 2026-03-12) says 'ASM is the leader in the fast-growing single-wafer ALD market – with a market share of 55%+ (ASM estimate, Investor Day 2025)'. It says ASM 'maintained leadership with our market share surpassing 55%' as the industry moved from FinFET to GAA. And it says that 'Based on the breadth of our R&D engagements and critical production-tool-of-record (PTOR) selections already secured in 2025, we expect to at least maintain our market share' into the 1.4nm node. The Q2 2026 results (https://www.asm.com/media/y0mkxj21/20260728-asm-reports-second-quarter-2026-results.pdf) say the 1.4nm node is on track for its first meaningful contribution in the second half of 2026, 'reflecting increased market share gains in both ALD and Epi'. 2025 gross margin was 51.8%. That is a strong, profitable position, but every share figure behind it is ASM's own estimate or expectation, and no independent share source supports it, so the rating is narrow rather than wide. The exposures also weigh: the five largest customers took about 53.6% of 2025 revenue and China more than 30%, and the report describes the main competitors as 'much larger companies from the United States and Asia'. | wide ASML's FY2025 20-F states it "is currently the world's only manufacturer of EUV lithography systems" — an effective monopoly on the extreme-ultraviolet tools required to pattern leading-edge logic and memory chips. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | intangibles ip The report grounds the ALD lead in accumulated process know-how and patents rather than unit cost: 'ASM has the broadest portfolio of ALD products with innovative ALD reactor designs. Our strength in chemistries and applications using new materials means our customers can meet advanced node technology challenges.' It also cites a LexisNexis PatentSight study finding that 'ASM holds a strong and impactful patent portfolio on its core strength of ALD as measured by both Competitive Impact and Patent Asset Index'. Switching friction reinforces this. Tools enter fabs through PTOR selection, the report notes that 'Failing a customer during a production ramp could create significant problems for them', and installed systems are supported 'with a view to having them in production 24/7 for 20+ years'. But ASM wins those PTOR slots node by node on process capability, which makes IP the primary source. | intangibles ip The durable advantage rests on decades of proprietary technology and IP — the 20-F describes ASML's April 2025 1,000-watt EUV light source as "built on 25 years of engineering advancements" — reinforced by an exclusive arrangement with Carl Zeiss SMT as its "sole supplier" of the critical optics no rival can source. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | co leader In single-wafer ALD, which is more than half of equipment sales, the report calls ASM 'the leader' with a 55%+ share. That share is ASM's own estimate; the Investor Day 2025 deck (https://www.asm.com/media/m3jhkm12/asm_investor_day_2025.pdf) sources it to 'ASM internal analysis and TechInsights'. With no independent share source, the band is held at co_leader rather than clear_leader. ASM does not lead every line: 'ASM has the number two share in the Epi equipment market', and in PECVD and vertical furnaces it is 'focused on niche portions of the market'. | clear leader Effectively 100% of the EUV market as the world's only EUV system maker; in the older DUV segment it "compete[s] primarily with Canon and Nikon" yet remains the leading supplier. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate Gross margin rose from 50.5% to 51.8% in 2025 and was 51.9% in Q2 2026. But the report attributes the 2025 gain to 'a very strong mix, including a continued solid contribution from the Chinese market' and to efficiency programs, not to price. It targets a range of 47% to 51% for 2026-2030, and the Q2 2026 release expects full-year 2026 gross margin 'to be around 51%'. Buyers are concentrated: the 10 largest customers were about 72.3% of 2025 revenue, the five largest about 53.6%, and two customers each contributed more than 10% of total revenue. | strong FY2025 gross margin of 52.8%, up 1.5 percentage points year over year, with management guiding toward 56-60% by 2030 — consistent with monopoly pricing power on EUV tools. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | ASM International, headquartered in the Netherlands, makes wafer-processing equipment with a focus on deposition: single-wafer ALD, silicon epitaxy, PECVD, vertical furnaces, silicon-carbide epitaxy and, since its acquisition of Axus in December 2025, CMP. Spares & Services made up 23% of 2025 revenue. ALD is the core. It was the largest product line, 'clearly accounting for more than half of our equipment sales', and ASM estimates its single-wafer ALD share at 55%+. The report frames ALD as increasingly necessary, saying 'ALD is the only deposition technology capable of meeting the coverage and film-property requirements for complex 3D structures', and expects ALD layers to grow in GAA transistor stacks, backside-power architectures and future 4F² DRAM. Epitaxy is the second-largest line: the report says ASM holds the number two share there and lifted its leading-edge share from 12% in 2020 to 25% in 2024, both by ASM's own figures. 2025 revenue reached a record €3.2 billion at a gross margin of 51.8%; per the Q2 2026 results, Q2 2026 revenue was €1,003 million at 51.9%. The exposures are customer concentration (the five largest customers were about 53.6% of 2025 revenue), geography (Asia was 80% of revenue and China more than 30%), and export restrictions that the report says are 'impacting our ability to sell and service systems in certain jurisdictions and for certain customers'. | ASML is the sole producer of EUV lithography systems, the only tools able to pattern the most advanced logic and memory nodes, with a roadmap "intended to drive affordable scaling to 2030 and beyond" and a High-NA EUV (TWINSCAN EXE) platform on which customers "had run more than 400,000 wafers" by end-2025. That dominance is protected by 25 years of accumulated engineering IP and an exclusive lock on Carl Zeiss SMT optics that competitors cannot replicate. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Upstream wafer-fab-equipment supplier to logic/foundry and memory chipmakers. 'The leading-edge logic/foundry market was the main growth driver for ASM, on the back of 2nm investments' in 2025, advanced-node DRAM was the largest part of memory sales, and Asia was 80% of revenue. | Upstream chokepoint of the AI chip supply chain: every leading-edge logic/DRAM wafer for AI accelerators is patterned on ASML EUV tools, making it the single indispensable equipment supplier to TSMC, Samsung and Intel. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.42 at weight 0.20 · swarm bullish Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |